LeonaBio

LONA on Nasdaq. Market value $33m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

Look carefully before going further

Why it could be worth it

Nothing stands out yet.

Read the warning sign in its own filings

This is not advice.

Compare with another stock

Who owns it

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

8 investors own more than 5%.

  • Sermonix Pharmaceuticals, Inc.
    at least 25.1%−11.8 pts
    (filed with 1 related holder)
    Since 26 October 2026
    What they said

    The assignment of the remaining prefunded warrant rights to acquire 2,352,932 common shares of Issuer effects the previously disclosed distribution-in-kind to PXV II as part of the plan of distribution to the owners of Sermonix's common stock as described in the original…

    Read the filing
  • Perceptive Advisors LLC
    Passive investor
    at least 20.0%0.0 pts
    (filed with 3 related holders)
    Since 26 October 2026
  • Anders Hove
    Passive investor
    at least 12.1%+5.9 pts
    (filed with 4 related holders)
    Since 18 August 2026
  • at least 7.7%
    (filed with 1 related holder)
    Since 31 March 2026
  • at least 5.0%
    (filed with 2 related holders)
    Since 28 October 2026
  • Spruce Street Capital LP
    Passive investor
    at least 4.2%
    (filed with 2 related holders)
    Since 30 September 2026
  • Oliveira Steven Michael
    Passive investor
    at least 4.1%−1.0 pts
    (filed with 3 related holders)
    Since 1 October 2025
  • Baselake Partners, LP
    Passive investor
    at least 1.9%−3.1 pts
    (filed with 2 related holders)
    Since 31 December 2025
  • BML Investment Partners, L.P.
    Passive investor
    Sold down below 5%
    Since 18 December 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 5 sold $99,418.

  • Renninger Robert
    CHIEF FINANCIAL OFFICER
    Sold
    Date
    4 March 2026
    Shares
    906
    Price
    $5.37
    Value
    $4,865
  • Worthington Mark
    GENERAL COUNSEL and CCO
    Sold
    Date
    4 March 2026
    Shares
    1,328
    Price
    $5.37
    Value
    $7,131
  • CHURCH KEVIN
    CHIEF SCIENTIFIC OFFICER
    Sold
    Date
    4 March 2026
    Shares
    1,359
    Price
    $5.37
    Value
    $7,298
  • San Martin Javier
    CHIEF MEDICAL OFFICER
    Sold
    Date
    4 March 2026
    Shares
    1,720
    Price
    $5.37
    Value
    $9,236
  • Litton Mark James
    PRESIDENT and CEO, Director
    Sold
    Date
    4 March 2026
    Shares
    5,156
    Price
    $5.37
    Value
    $27,688
  • Renninger Robert
    Chief Financial Officer
    Sold
    Date
    2 January 2026
    Shares
    297
    Price
    $6.88
    Value
    $2,043
  • Worthington Mark
    General Counsel and CCO
    Sold
    Date
    2 January 2026
    Shares
    876
    Price
    $6.88
    Value
    $6,027
  • CHURCH KEVIN
    CHIEF SCIENTIFIC OFFICER
    Sold
    Date
    2 January 2026
    Shares
    876
    Price
    $6.88
    Value
    $6,027
  • San Martin Javier
    CHIEF MEDICAL OFFICER
    Sold
    Date
    2 January 2026
    Shares
    1,644
    Price
    $6.88
    Value
    $11,311
  • Litton Mark James
    President and CEO, Director
    Sold
    Date
    2 January 2026
    Shares
    2,586
    Price
    $6.88
    Value
    $17,792

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in LeonaBio’s filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 31 Mar 2026, plus the 10-Q filed 16 Nov 2026 and 6 later 8-Ks.

  • Doubt it can keep going

    Serious

    The company or its auditor warned it may not have enough money to last the next year.

    “Based upon the Company’s current operating plan, it estimates that its $ 32.3 million of cash, cash equivalents and investments at September 30, 2026 will not be sufficient to fund its operating expenses and capital expenditure requirements under its current operating plan for at least the next 12 months, which raises substantial doubt as to the Company's ability to continue as a going concern following the date of this Quarterly Report on Form 10-Q.”
    Show the full paragraph
    Based upon the Company’s current operating plan, it estimates that its $ 32.3 million of cash, cash equivalents and investments at September 30, 2026 will not be sufficient to fund its operating expenses and capital expenditure requirements under its current operating plan for at least the next 12 months, which raises substantial doubt as to the Company's ability to continue as a going concern following the date of this Quarterly Report on Form 10-Q. Historically, the Company has incurred net losses from continuing operations and negative operating cash flows. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs; therefore, the Company expects it will need to continue to raise additional capital to accomplish its operating plan.

    From the 10-Q filed 16 November 2026, Part I, Item 1. Financial Statements. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from

A serious warning sign just appeared in its filings. Read what it says before you buy.

Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.